athletes because AF limits performance in horses used for intensive athletic work. Even at lower levels of exercise intensity, horses in AF might exhibit extremely high heart rates (HRs), and collapse has been described. 1 The success rate for both pharmacological cardioversion and TVEC is very high, but AF recurrence after treatment is common with an overall rate of recurrence up to 39% at 1 year after cardioversion. [2] [3] [4] [5] The pathophysiology of AF initiation and perpetuation in horses has not yet been completely elucidated. Factors that might be associated with AF recurrence include structural changes to the atrial myocardium, atrial size and stretch, short atrial effective refractory period (AERP), and supraventricular ectopic foci. 2, 6 Long-term antiarrhythmic treatment could be used to prevent AF recurrence after cardioversion through different mechanisms such as increasing AERP, decreasing supraventricular ectopy, and decreasing vulnerability to AF initiation. As has been shown in humans, dogs, and horses, sotalol and other class III antiarrhythmic drugs lead to lengthening of the repolarization phase of the action potential by blocking the outward rapid delayed rectifier potassium current. This leads to an increase in refractoriness of the tissues. Aside from reversing the shortening of the monophasic action potential and effective refractory period (ERP) caused by atrial remodeling during AF, lengthening of the ERP also decreases the excitability of the cardiac tissues. Therefore, a decrease in ectopic discharges and a decrease in substrate for re-entry are likely. In addition, antiarrhythmic treatment might be useful to decrease the HR at rest or during exertion in horses in AF.
This rate control therapy possibly could decrease the risk of collapse and sudden cardiac death. However, long-term PO antiarrhythmic therapy is rare in horses, and the drugs also might have proarrhythmic effects.
Sotalol can be safely administered with intermediate PO bioavailability in horses. 7 In human medicine, sotalol is not commonly used for cardioversion of AF, but it is frequently used as an effective drug for prevention of AF recurrence after cardioversion. 8, 9 Electrophysiological effects of sotalol include increased QT interval, decreased HR, and prolongation of the atrioventricular nodal refractory period and PQ interval. In veterinary medicine, sotalol is the most commonly used long-term treatment for hemodynamically important ventricular arrhythmias in dogs and cats. 10 In healthy horses, sotalol results in prolongation of the QT interval. 7, 11 However, the use of sotalol has not been described in horses with cardiac arrhythmias, except in 2 recent reports describing single cases. 12, 13 Our objectives were to assess the effect of sotalol on HR, QT interval, atrial fibrillatory rate, and success of cardioversion in horses with AF. We hypothesized that sotalol administration would result in a decreased HR at rest and during exercise, a prolonged QT interval and a decreased atrial fibrillatory rate.
| M A TE RI A L S A ND M E TH ODS

| Study design
The study population consisted of 41 horses consecutively admitted for TVEC treatment of AF at the Department of Large Animal Internal Medicine at the Faculty of Veterinary Medicine, Ghent University. All horses were examined by an ECG at rest of at least 2 hours duration, an ECG during a lunging exercise test 14 and echocardiography. After the initial measurements at admission, the first 28 horses were treated PO with 2 mg/kg sotalol (Sotalol Sandoz, Sandoz, Vilvoorde, Belgium) q12h for 3 days before cardioversion. Echocardiography was repeated just before TVEC, after 6 doses of sotalol had been administered. The ECG at rest was repeated after at least 5 doses of sotalol, and the exercise test after at least 4 doses of sotalol. Data always were collected approximately 2-3 hours after sotalol administration. To determine measurement repeatability, 13
horses underwent the same protocol without sotalol administration. The TVEC was performed according to procedures described previously. 4, 15 Shocks were administered under general anesthesia using stepwise increases of the delivered energy (150, 200, 250, 300, and 360 J) until cardioversion. If cardioversion did not occur after the 360 J shock, the catheters were repositioned and more high energy shocks were administered.
| Measurements
The HR at rest was measured from the resting ECG (Televet 100, Engel
Engineering Services GmbH, Heusenstamm, Germany) as an average over a 30-minute period. The QT interval was measured at rest using the Televet software calipers (Televet 100, Engel Engineering Services GmbH), as an average from 10 RR intervals with an instantaneous HR of the preceding RR interval of 35-45 bpm. 16 The lunging exercise test consisted of 5 minutes of walk, 10 minutes of trot, 4 minutes of canter, and 1 minute of gallop. The test was terminated early if the horse showed an excessively high HR or frequent QRS complexes with an R-on-T morphology. The HR at walk, trot, and canter was measured over 2 minutes, starting at least 1 minute after the gait transition in order to obtain a relatively stable HR.
The HR during gallop was measured over the entire gallop phase.
The atrial fibrillatory rate was assessed from tissue Doppler velocity curves of the atrial myocardial walls, as described previously. 
| Statistics
The number of horses that received sotalol was determined using power calculation software (G*Power 3. between the sotalol group and the control group using an independent t test for normally distributed variables or the Mann-Whitney test for non-normally distributed data. The level of significance was defined as P < .05.
| R E SU LTS
The sotalol group consisted of 23 Warmbloods, 3 trotters, 1 Paint, and The resting HR, QT interval, HRs during exercise, and AFCL before and after treatment are summarized in Table 1 for the sotalol group and the control group. Within the sotalol group, the resting HR and the HRs during exercise decreased after treatment compared to before treatment ( Figure 3A) , whereas the QT interval and the AFCL measured in the right atrium and the left atrial free wall from the left parasternal view increased. In the control group, no significant differences were found between the 2 examinations ( Figure 3B ). Compared to the control group, horses in the sotalol group had lower resting HR, lower HR during trot and increased QT interval.
| D ISC USSION
We describe the effects of sotalol administered PO to horses with AF.
Sotalol treatment resulted in a decrease in HR at rest and during exercise, a prolongation of the QT interval and an increase in AFCL. Significantly less energy was required for electrical cardioversion in the sotalol group, although cardioversion could not be achieved in 3/28
horses, of which 1 horse converted during a second TVEC procedure.
FIG URE 2
High heart rate and QRS complexes with an R-on-T morphology in 1 horse in the sotalol group, after which the exercise test was terminated early Abbreviations: HR rest, heart rate at rest; bpm, beats per minute; QT rest, QT interval at rest; HR walk, heart rate during walk; HR trot, heart rate during trot; HR canter, heart rate during canter; HR gallop, heart rate during gallop; AFCL 4CH , atrial fibrillation cycle length measured in the left atrial free wall from the 4 chamber view; AFCL RA , atrial fibrillation cycle length from the right atrial dorsal wall at the level of the tuberculum intervenosum in a right parasternal view; AFCL LLA , atrial fibrillation cycle length measured in the left atrial free wall from the left parasternal long-axis view. Significant differences between groups are indicated by different superscripts (P < .05).
The increased AFCL after sotalol treatment indicates slowing of the atrial activation rate. During AF, the AFCL is somewhat longer than the AERP because of the presence of a small excitable gap. 19 The prolongation of AFCL after sotalol administration can be attributed to an increase in the AERP or to widening of the temporal excitable gap. A previous study in goats described a 24% increase of the AFCL during IV sotalol infusion at 0.2 mg/kg/min. 20 This mainly resulted from widening of the temporal excitable gap, while the AERP remained stable.
Sotalol administration in our study resulted in a modest increase of AFCL by approximately 6%. In comparison, IV administration of the class III antiarrhythmic drug amiodarone caused an AFCL increase up to 100% in horses with naturally occurring chronic AF. 21 In another study, the class I drug flecainide administered IV to horses resulted in an AFCL increase of approximately 35-50%. 22, 23 This is in line with the experimental study in goats, where administration of flecainide caused an AFCL increase of 48%. 20 This was attributed to widening of the temporal excitable gap, which results in decreased fragmentation of wavelets and fusion of waves. This causes a reduction of the number of wavelets in the atria and thus an increased chance of cardioversion. 22 Compared to amiodarone or flecainide, the effect of 2 mg/kg sotalol PO q12h on AFCL was limited, and cardioversion of AF using sotalol therapy alone seems unlikely in horses.
The limited effects of sotalol on AFCL can be explained by several factors. First, the sotalol plasma concentrations were probably below the therapeutic range described in human medicine. Plasma concentrations were not measured in our study, but the steady state plasma concentration was 287 ng/mL in horses receiving 2 mg/kg body weight sotalol PO twice daily for 9 days, while fed hay ad libitum during the day. 11 This is lower than the therapeutic plasma concentrations of 1000-3000 ng/mL described in human medicine. 24 However, the significant QT prolongation indicates class III activity despite the low plasma concentrations. The limited effects on the AFCL also can be explained by the reverse use dependence of the effect of sotalol on atrial refractoriness, implying decreased class III effects at more rapid atrial rates. 25 Reverse use dependence of sotalol probably limits the efficacy of sotalol against naturally occurring chronic AF with short AFCL, compared to use-dependent drugs such as propafenone. Finally, the effect of sotalol also might be affected by electrical remodeling of the atrial myocardium. Decreased electrophysiological actions of class III antiarrhythmic agents have been described in a goat model of chronic AF, and was explained by decreased contribution of the rapid delayed rectifier potassium current (IKr) to atrial repolarization in remodeled myocardium. 26 The AFCL measured in the left atrial free wall from the right parasternal 4-chamber view was shorter compared to the other views, as has been described previously. 17, 18 The AFCL from this view did not show a significant increase after sotalol administration. In the 4 chamber view, the atrial myocardium is located at a large image depth and horses. Based on our study, it is unclear whether sotalol therapy could permanently decrease the exercising HR in horses with AF and whether riding a horse on sotalol is safe. First, the presence of QRS complexes with an R-on-T morphology was not decreased after sotalol treatment, and this might be associated with increased risk of ventricular fibrillation. 14 Second, sotalol is not recommended for rate control therapy in human medicine because of the risk of torsades de pointes and sudden cardiac death associated with QT prolongation. 29 The QT prolongation in our study was limited to 9%, whereas in human medicine an increase of 15%-20% is considered dangerous. Excessive QT prolongation might occur in horses when sotalol therapy is combined with other drugs, as has been described with general anesthesia. 30 Third, the b-blocking activity of sotalol might result in a negative inotropic effect and might affect blood pressure during exercise. However, the negative inotropic effect is counteracted by the class III activity, and no alterations of blood pressure have been described at rest in horses receiving sotalol. 11 Finally, sotalol cannot be used in horses during competition, because it is listed in the F ed eration Equestre Internationale prohibited substances database as a controlled medication.
In human medicine, sotalol is used to maintain sinus rhythm after cardioversion of AF, although proarrhythmogenic effects and a small increase in all-cause mortality have been associated with its use. 31 Our study did not evaluate whether sotalol decreases the risk of AF recurrence, because doing so would require a long-term follow-up study in which horses are randomly treated with sotalol or placebo after cardioversion. 32 The main limitation of our study is that sotalol was not administered in a double-blinded fashion with random assignment of horses to either the treatment group or the control group. Instead, all horses admitted for AF treatment in the timespan of 1 year were administered sotalol before TVEC as part of the standard treatment protocol. The control group consisted of horses consecutively admitted for AF treatment in a different calendar year, during which sotalol administration was not part of the treatment protocol because of safety concerns when combined with general anesthesia or administration of amiodarone in case of early recurrence of AF. The same study protocol was followed. Therefore, no difference between the 2 groups was expected.
In conclusion, sotalol administration results in class III antiarrhythmic effects and b-blocking activity in horses with AF. Therefore, sotalol shows potential as a rate control drug in exercising horses with AF.
However, the safety of sotalol administration needs further evaluation because the HR reduction after sotalol therapy was limited, the risk of R-on-T phenomenon was not decreased and the proarrhythmic effects during exercise are not known. 
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